Prakash Chandwani1, Jayesh Prajapati2, Sanjay Porwal3, Bhavesh Khambhati4, Ashok Thakkar5. 1. Director, Department of Cardiology, Heart and General Hospital , 7, Vivekanand Marg, C-Scheme, Jaipur, India . 2. Senior Interventional Cardiologist, Department of Cardiology, Apollo Hospitals International Limited , Gandhinagar, Gujarat, India. . 3. Associate Professor, Department of Cardiology, KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre , Belgaum, Karnataka, India . 4. Senior Clinical Research Associate, Department of Clinical Trials, Sahajanand Medical Technologies Pvt. Ltd , Surat, Gujarat, India . 5. Senior Manager, Clinical Research and Medical Writing, Department of Clinical Trials, Sahajanand Medical Technologies Pvt. Ltd , Surat, Gujarat, India .
Abstract
INTRODUCTION: Coronary artery disease is the most common catastrophic disease in India. The safety and effectiveness of dual vessel sirolimus-eluting stent (SES) implantation (used as an intervention in CAD) is currently unknown in Indian population. The purpose of this study was to investigate one year clinical outcomes of patients with dual vessel coronary artery disease after implantation of the Supralimus-Core SES, in a "real-world" setting. MATERIALS AND METHODS: We evaluated 60 patients between April-2011 and August-2012, who underwent dual vessel percutaneous coronary intervention (PCI) with the Supralimus-Core SES implantation at the same index procedure. Dual vessels were defined as involvement of two major epicardial vessels (right, left anterior descending, circumflex, or left main coronary arteries) or one major epicardial vessel and a branch (≥2.5 mm in diameter) originating from another major epicardial vessel. The primary endpoint was target lesion failure (TLF) defined as the composite of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR) at one year. Secondary endpoint included combined (definite, probable and possible) stent thrombosis (ST). RESULTS: A total of 120 lesions were treated in 60 enrolled patients (mean age 56.0±9.2 y; 80.0% male) with average stent length of 23.1±8.5 mm. Among 60 patients, diabetes, hypertension and hypercholesterolemia were present in 15 (25.0%), 22 (36.7%) and 25 (41.7%) patients respectively. Indications for PCI were unstable angina in 30 (50.0%) patients and stable angina in 11 (18.3%) patients. Overall, 40 (33.3%) lesions were classified as complex (American College of Cardiology/American Heart Association type B2/C). The cumulative TLF rate was 5.0% (n=3) at one year. Cardiac death, MI and clinically-driven TLR occurred in 1 (1.7%), 0 (0%) and 2 (3.3%) patients, respectively at one year follow-up. The Kaplan-Meier curve of the freedom from overall events at one year was 95.0%. According to the Academic Research Consortium definition, there were no events of stent thrombosis during one year. CONCLUSION: Our study shows that, dual vessel Supralimus-Core SES implantation allows safe and effective treatment with low rates of TLF at one year follow-up in Indian population.
INTRODUCTION:Coronary artery disease is the most common catastrophic disease in India. The safety and effectiveness of dual vessel sirolimus-eluting stent (SES) implantation (used as an intervention in CAD) is currently unknown in Indian population. The purpose of this study was to investigate one year clinical outcomes of patients with dual vessel coronary artery disease after implantation of the Supralimus-Core SES, in a "real-world" setting. MATERIALS AND METHODS: We evaluated 60 patients between April-2011 and August-2012, who underwent dual vessel percutaneous coronary intervention (PCI) with the Supralimus-Core SES implantation at the same index procedure. Dual vessels were defined as involvement of two major epicardial vessels (right, left anterior descending, circumflex, or left main coronary arteries) or one major epicardial vessel and a branch (≥2.5 mm in diameter) originating from another major epicardial vessel. The primary endpoint was target lesion failure (TLF) defined as the composite of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR) at one year. Secondary endpoint included combined (definite, probable and possible) stent thrombosis (ST). RESULTS: A total of 120 lesions were treated in 60 enrolled patients (mean age 56.0±9.2 y; 80.0% male) with average stent length of 23.1±8.5 mm. Among 60 patients, diabetes, hypertension and hypercholesterolemia were present in 15 (25.0%), 22 (36.7%) and 25 (41.7%) patients respectively. Indications for PCI were unstable angina in 30 (50.0%) patients and stable angina in 11 (18.3%) patients. Overall, 40 (33.3%) lesions were classified as complex (American College of Cardiology/American Heart Association type B2/C). The cumulative TLF rate was 5.0% (n=3) at one year. Cardiac death, MI and clinically-driven TLR occurred in 1 (1.7%), 0 (0%) and 2 (3.3%) patients, respectively at one year follow-up. The Kaplan-Meier curve of the freedom from overall events at one year was 95.0%. According to the Academic Research Consortium definition, there were no events of stent thrombosis during one year. CONCLUSION: Our study shows that, dual vessel Supralimus-Core SES implantation allows safe and effective treatment with low rates of TLF at one year follow-up in Indian population.
Authors: Stuart N Hoffman; John A TenBrook; Michael P Wolf; Stephen G Pauker; Deeb N Salem; John B Wong Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: R Kornowski; R Mehran; L F Satler; A D Pichard; K M Kent; A Greenberg; G S Mintz; M K Hong; M B Leon Journal: J Am Coll Cardiol Date: 1999-02 Impact factor: 24.094
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: Victor M G Legrand; Patrick W Serruys; Felix Unger; Ben A van Hout; Mathias C M Vrolix; Geert M P Fransen; Torsten Toftegaard Nielsen; Peter Kildeberg Paulsen; Ricardo Seabra Gomes; João M G de Queiroz e Melo; José P Marques dos Santos Neves; Wietze Lindeboom; Bianca Backx Journal: Circulation Date: 2004-03-01 Impact factor: 29.690
Authors: M Lambert; R Bonan; G Coté; J Crépeau; P de Guise; J Lespérance; P R David; D D Waters Journal: Am J Cardiol Date: 1987-10-01 Impact factor: 2.778